Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 2.0 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AbbVie Inc.; Eisai Inc.; Genmab US, Inc.; and Seattle Genetics.

Community Practice Connections™: 11th Annual International Symposium on Ovarian Cancer and Gynecologic Malignancies

Release Date: July 31, 2020
Expiration Date: July 31, 2021

Activity Overview

The field of gynecologic cancers has seen breakthroughs in treatment options in recent years, including the integration of targeted therapies and immunotherapeutics into clinical practice. Optimal implementation of surgery, chemotherapy, PARP inhibitors, antiangiogenesis agents, checkpoint blockade, as well as combination and other therapeutic strategies are analyzed and discussed both in frontline and recurrent disease settings. Case-based presentations allow for discussion of the practical concerns of treating patients in the real world. Promising novel agents currently undergoing clinical trial evaluation are also highlighted.

This Community Practice Connection™ program provides an in-depth review of some of the key highlights from live, virtual symposium, 11th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies™, hosted on in May 2020. This unique and engaging multi-media activity is ideal for the community-based clinician and focuses on the practical aspects of managing patients with gynecologic cancers, putting recent clinical trial data into clinical context. The program is designed to provide information for those who did not attend the live meeting and to help reinforce learnings for those who did.

Acknowledgement of Commercial Support

This activity is supported by educational grants from AbbVie Inc.; Eisai Inc.; Genmab US, Inc.; and Seattle Genetics.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational activity is directed toward medical oncologists, gynecologic oncologists, and surgical oncologists who treat patients with gynecologic malignancies. Radiation oncologists, nurse practitioners, nurses, physician assistants, pharmacists, researchers, fellows, and other healthcare professionals interested in the treatment of gynecologic malignancies will be invited to participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Understand the design, efficacy, and safety data of clinical trials designed to investigate novel compounds and strategies for the management of gynecologic malignancies
  • Apply the new findings and recently presented data in a clinical context, and understand their therapeutic implications for the management of gynecologic malignancies
  • Potentiate trial enrollment for eligible patients in order to evaluate new agents or strategies in the treatment of gynecologic malignancies

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Program Chair

Ursula A. Matulonis, MD
Ursula A. Matulonis, MD
Director and Chief, Division of Gynecologic Oncology
Brock-Wilson Family Chair
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, MA

Disclosures: Consultant: Eisai, Tesaro. Other: Travel: AstraZeneca.


Bradley J. Monk, MD, FACOG, FACS
Bradley J. Monk, MD, FACOG, FACS
Professor and Director, Division of Gynecologic Oncology
Creighton University School of Medicine
St. Joseph's Hospital and Medical Center
Medical Director, US Oncology Network – Gynecologic Oncology Research
Phoenix, AZ

Disclosures: Consultant: AbbVie, Advaxis, Amgen, AstraZeneca, Biodesix, Clovis Oncology, Genmab, Gradalis, ImmunoGen, Incyte Corporation, Insys Therapeutics, Mateon Therapeutics, Merck & Co, Myriad Genetics, Perthera, Pfizer, Precision Oncology, Roche/Genentech, Samumed, Takeda, Tesaro, VBL Therapeutics. Speakers Bureau: AstraZeneca, Clovis Oncology, Janssen/Johnson & Johnson, Roche/Genentech, Tesaro.

Ramez N. Eskander, MD
Ramez N. Eskander, MD
Associate Clinical Professor of Gynecologic Oncology
Fellowship Director
Associate Residency Program Director
UC San Diego Moores Cancer Center
La Jolla, CA

Disclosures: Consultant: AstraZeneca, Clovis Oncology, Eisai, GlaxoSmithKline/Tesaro, Iovance Biotherapeutics. Speakers Bureau: AstraZeneca, Clovis Oncology.

Shannon N. Westin MD, MPH
Shannon N. Westin MD, MPH
Associate Professor
Director, Early Drug Development
Department of Gynecologic Oncology and Reproductive Medicine
UT MD Anderson Cancer Center

Disclosures: Grant/Research Support: ArQule, AstraZeneca, Bayer, Clovis Oncology, Cotinga Pharmaceuticals, GSK/Tesaro, Novartis, Roche/Genentech. Consultant: AstraZeneca, Circulogene Theranostics, Clovis Oncology, Eisai, GSK/Tesaro, Merck & Co, Novartis, Pfizer, Roche/Genentech.

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By